Evaluation of WO2012032067 and WO2012055846: two selective PI3Kδ inhibitors, which is GSK-2269557?
Two applications each claim crystalline forms, salts and compositions of a single selective PI3Kδ inhibitor. The subject of both applications are specific, previously disclosed, 6-aryl-4-(5-aminomethyloxazol-2-yl)indazole derivatives, respectively N-[5-[4-[5-[[(2R,6S)-2,6-dimethylmorpholin-4-yl]methyl]oxazol-2-yl]-1H-indazol-6-yl]-2-methoxy-3-pyridyl]methanesulfonamide and 2-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-5-[(4-isopropylpiperazin-1-yl)methyl]oxazole.